Factors Affecting the Outcome of Related Allogeneic Hematopoietic Cell Transplantation in Patients with Fanconi Anemia
Abstract Hematopoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi Anemia (FA), and it is generally accepted that these patients should receive low-intensity conditioning because of the underlying DNA repair defect in their cells. Outcomes for recipients of match...
Gespeichert in:
Veröffentlicht in: | Biology of blood and marrow transplantation 2014-10, Vol.20 (10), p.1599-1603 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1603 |
---|---|
container_issue | 10 |
container_start_page | 1599 |
container_title | Biology of blood and marrow transplantation |
container_volume | 20 |
creator | Ayas, Mouhab Siddiqui, Khawar Al-Jefri, Abdullah El-Solh, Hassan Al-Ahmari, Ali Khairy, Ashraf Markiz, Samer Shahin, Hasan Al-Musa, Abdulrahman Al-Seraihy, Amal |
description | Abstract Hematopoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi Anemia (FA), and it is generally accepted that these patients should receive low-intensity conditioning because of the underlying DNA repair defect in their cells. Outcomes for recipients of matched related HCT have generally been favorable, but only a few studies have scrutinized the factors that may affect the eventual outcome of these patients. This retrospective analysis of 94 pediatric patients with FA who underwent related HCT at King Faisal Specialist Hospital & Research Center was carried out to attempt to identify factors that may affect outcome. Results showed overall survival (OS) probabilities of 92.5%, 89%, and 86% at 1, 5, and 10 years, respectively. In univariate analysis, use of higher dose cyclophosphamide (CY) (60 mg/kg) conditioning was associated with a better 10-year OS than lower dose CY (20 mg/kg) conditioning (91% versus 82%, respectively; P = .035), and use of radiation-containing regimens was associated with a significantly lower 10-year OS than nonradiation regimens (76% versus 91%, respectively; P = .005). Of the 4 regimens used in this study, the fludarabine-based regimen was associated with the highest survival (95.2%; P = .034). The use of the higher dose CY (60 mg/kg) was associated with a significantly increased incidence of hemorrhagic cystitis (HC) (20% versus 5.6% respectively; P = .049). Three patients (3%) developed squamous cell carcinoma (2 oropharyngeal and 1 genitourinary), at 9.4, 5.4, and 13.3 years after HCT; 2 of them had radiation-containing conditioning. In conclusion, our data suggest that although using a higher dose CY (60 mg/kg) conditioning regimen may be associated with better survival, it is also associated with a significantly increased risk of HC. The addition of fludarabine to the low-dose CY (20 mg/kg) is associated with the best survival. On the other hand, radiation-containing regimens are associated with significantly lower survival. |
doi_str_mv | 10.1016/j.bbmt.2014.06.016 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1561971028</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1083879114003668</els_id><sourcerecordid>1561971028</sourcerecordid><originalsourceid>FETCH-LOGICAL-c488t-432b1ac9b42e98a95ec2d252eb482ab8f156eb7ac039f0a007aa49a57739bbdc3</originalsourceid><addsrcrecordid>eNp9kUFv1DAQhSMEoqXwBzggH7kk2E7i2BJCWq1YilSpCMrZGjuT1ktiL7ZT1H-PV1s4cODk8ei9p5lvquo1ow2jTLzbN8YsueGUdQ0VTWk9qc5Zz9ta9K14Wmoq21oOip1VL1LaU0qHTqrn1RnvlKCCy_Pqfgc2h5jIZprQZudvSb5Dcr1mGxYkYSJfcYaMI9nMc7hFj86SS1wgh0NwmMtvi_NMbiL4dJjBZ8gueOI8-VIq9DmRXy7fkR14G7wjG4-Lg5fVswnmhK8e34vq--7jzfayvrr-9Hm7uaptJ2Wuu5YbBlaZjqOSoHq0fOQ9R9NJDkZOrBdoBrC0VROFsh9Ap6AfhlYZM9r2onp7yj3E8HPFlPXiki0Dg8ewJl38TA2Mclmk_CS1MaQUcdKH6BaID5pRfeSt9_rIWx95ayp0aRXTm8f81Sw4_rX8AVwE708CLFveO4w62ULF4uhi4a3H4P6f_-Efu52ddxbmH_iAaR_W6As_zXTimupvx4sfD846SlshZPsb4-Cnyw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1561971028</pqid></control><display><type>article</type><title>Factors Affecting the Outcome of Related Allogeneic Hematopoietic Cell Transplantation in Patients with Fanconi Anemia</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Ayas, Mouhab ; Siddiqui, Khawar ; Al-Jefri, Abdullah ; El-Solh, Hassan ; Al-Ahmari, Ali ; Khairy, Ashraf ; Markiz, Samer ; Shahin, Hasan ; Al-Musa, Abdulrahman ; Al-Seraihy, Amal</creator><creatorcontrib>Ayas, Mouhab ; Siddiqui, Khawar ; Al-Jefri, Abdullah ; El-Solh, Hassan ; Al-Ahmari, Ali ; Khairy, Ashraf ; Markiz, Samer ; Shahin, Hasan ; Al-Musa, Abdulrahman ; Al-Seraihy, Amal</creatorcontrib><description>Abstract Hematopoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi Anemia (FA), and it is generally accepted that these patients should receive low-intensity conditioning because of the underlying DNA repair defect in their cells. Outcomes for recipients of matched related HCT have generally been favorable, but only a few studies have scrutinized the factors that may affect the eventual outcome of these patients. This retrospective analysis of 94 pediatric patients with FA who underwent related HCT at King Faisal Specialist Hospital & Research Center was carried out to attempt to identify factors that may affect outcome. Results showed overall survival (OS) probabilities of 92.5%, 89%, and 86% at 1, 5, and 10 years, respectively. In univariate analysis, use of higher dose cyclophosphamide (CY) (60 mg/kg) conditioning was associated with a better 10-year OS than lower dose CY (20 mg/kg) conditioning (91% versus 82%, respectively; P = .035), and use of radiation-containing regimens was associated with a significantly lower 10-year OS than nonradiation regimens (76% versus 91%, respectively; P = .005). Of the 4 regimens used in this study, the fludarabine-based regimen was associated with the highest survival (95.2%; P = .034). The use of the higher dose CY (60 mg/kg) was associated with a significantly increased incidence of hemorrhagic cystitis (HC) (20% versus 5.6% respectively; P = .049). Three patients (3%) developed squamous cell carcinoma (2 oropharyngeal and 1 genitourinary), at 9.4, 5.4, and 13.3 years after HCT; 2 of them had radiation-containing conditioning. In conclusion, our data suggest that although using a higher dose CY (60 mg/kg) conditioning regimen may be associated with better survival, it is also associated with a significantly increased risk of HC. The addition of fludarabine to the low-dose CY (20 mg/kg) is associated with the best survival. On the other hand, radiation-containing regimens are associated with significantly lower survival.</description><identifier>ISSN: 1083-8791</identifier><identifier>EISSN: 1523-6536</identifier><identifier>DOI: 10.1016/j.bbmt.2014.06.016</identifier><identifier>PMID: 24960628</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Carcinoma, Squamous Cell - chemically induced ; Carcinoma, Squamous Cell - immunology ; Carcinoma, Squamous Cell - mortality ; Carcinoma, Squamous Cell - pathology ; Child ; Child, Preschool ; Cyclophosphamide ; Cyclophosphamide - adverse effects ; Cystitis - chemically induced ; Cystitis - immunology ; Cystitis - mortality ; Cystitis - pathology ; Fanconi anemia ; Fanconi Anemia - immunology ; Fanconi Anemia - mortality ; Fanconi Anemia - pathology ; Fanconi Anemia - therapy ; Female ; Gamma Rays - adverse effects ; Hematology, Oncology and Palliative Medicine ; Hematopoietic Stem Cell Transplantation ; Hemorrhage - chemically induced ; Hemorrhage - immunology ; Hemorrhage - mortality ; Hemorrhage - pathology ; Histocompatibility Testing ; Humans ; Infant ; Male ; Myeloablative Agonists - adverse effects ; Oropharyngeal Neoplasms - chemically induced ; Oropharyngeal Neoplasms - immunology ; Oropharyngeal Neoplasms - mortality ; Oropharyngeal Neoplasms - pathology ; Radiation ; Retrospective Studies ; Siblings ; Stem cell transplantation ; Survival Analysis ; Transplantation Conditioning - methods ; Transplantation, Homologous ; Unrelated Donors ; Vidarabine - adverse effects ; Vidarabine - analogs & derivatives</subject><ispartof>Biology of blood and marrow transplantation, 2014-10, Vol.20 (10), p.1599-1603</ispartof><rights>American Society for Blood and Marrow Transplantation</rights><rights>2014 American Society for Blood and Marrow Transplantation</rights><rights>Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c488t-432b1ac9b42e98a95ec2d252eb482ab8f156eb7ac039f0a007aa49a57739bbdc3</citedby><cites>FETCH-LOGICAL-c488t-432b1ac9b42e98a95ec2d252eb482ab8f156eb7ac039f0a007aa49a57739bbdc3</cites><orcidid>0000-0002-8732-5611</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bbmt.2014.06.016$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24960628$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ayas, Mouhab</creatorcontrib><creatorcontrib>Siddiqui, Khawar</creatorcontrib><creatorcontrib>Al-Jefri, Abdullah</creatorcontrib><creatorcontrib>El-Solh, Hassan</creatorcontrib><creatorcontrib>Al-Ahmari, Ali</creatorcontrib><creatorcontrib>Khairy, Ashraf</creatorcontrib><creatorcontrib>Markiz, Samer</creatorcontrib><creatorcontrib>Shahin, Hasan</creatorcontrib><creatorcontrib>Al-Musa, Abdulrahman</creatorcontrib><creatorcontrib>Al-Seraihy, Amal</creatorcontrib><title>Factors Affecting the Outcome of Related Allogeneic Hematopoietic Cell Transplantation in Patients with Fanconi Anemia</title><title>Biology of blood and marrow transplantation</title><addtitle>Biol Blood Marrow Transplant</addtitle><description>Abstract Hematopoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi Anemia (FA), and it is generally accepted that these patients should receive low-intensity conditioning because of the underlying DNA repair defect in their cells. Outcomes for recipients of matched related HCT have generally been favorable, but only a few studies have scrutinized the factors that may affect the eventual outcome of these patients. This retrospective analysis of 94 pediatric patients with FA who underwent related HCT at King Faisal Specialist Hospital & Research Center was carried out to attempt to identify factors that may affect outcome. Results showed overall survival (OS) probabilities of 92.5%, 89%, and 86% at 1, 5, and 10 years, respectively. In univariate analysis, use of higher dose cyclophosphamide (CY) (60 mg/kg) conditioning was associated with a better 10-year OS than lower dose CY (20 mg/kg) conditioning (91% versus 82%, respectively; P = .035), and use of radiation-containing regimens was associated with a significantly lower 10-year OS than nonradiation regimens (76% versus 91%, respectively; P = .005). Of the 4 regimens used in this study, the fludarabine-based regimen was associated with the highest survival (95.2%; P = .034). The use of the higher dose CY (60 mg/kg) was associated with a significantly increased incidence of hemorrhagic cystitis (HC) (20% versus 5.6% respectively; P = .049). Three patients (3%) developed squamous cell carcinoma (2 oropharyngeal and 1 genitourinary), at 9.4, 5.4, and 13.3 years after HCT; 2 of them had radiation-containing conditioning. In conclusion, our data suggest that although using a higher dose CY (60 mg/kg) conditioning regimen may be associated with better survival, it is also associated with a significantly increased risk of HC. The addition of fludarabine to the low-dose CY (20 mg/kg) is associated with the best survival. On the other hand, radiation-containing regimens are associated with significantly lower survival.</description><subject>Adolescent</subject><subject>Carcinoma, Squamous Cell - chemically induced</subject><subject>Carcinoma, Squamous Cell - immunology</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cyclophosphamide</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Cystitis - chemically induced</subject><subject>Cystitis - immunology</subject><subject>Cystitis - mortality</subject><subject>Cystitis - pathology</subject><subject>Fanconi anemia</subject><subject>Fanconi Anemia - immunology</subject><subject>Fanconi Anemia - mortality</subject><subject>Fanconi Anemia - pathology</subject><subject>Fanconi Anemia - therapy</subject><subject>Female</subject><subject>Gamma Rays - adverse effects</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hemorrhage - chemically induced</subject><subject>Hemorrhage - immunology</subject><subject>Hemorrhage - mortality</subject><subject>Hemorrhage - pathology</subject><subject>Histocompatibility Testing</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>Myeloablative Agonists - adverse effects</subject><subject>Oropharyngeal Neoplasms - chemically induced</subject><subject>Oropharyngeal Neoplasms - immunology</subject><subject>Oropharyngeal Neoplasms - mortality</subject><subject>Oropharyngeal Neoplasms - pathology</subject><subject>Radiation</subject><subject>Retrospective Studies</subject><subject>Siblings</subject><subject>Stem cell transplantation</subject><subject>Survival Analysis</subject><subject>Transplantation Conditioning - methods</subject><subject>Transplantation, Homologous</subject><subject>Unrelated Donors</subject><subject>Vidarabine - adverse effects</subject><subject>Vidarabine - analogs & derivatives</subject><issn>1083-8791</issn><issn>1523-6536</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUFv1DAQhSMEoqXwBzggH7kk2E7i2BJCWq1YilSpCMrZGjuT1ktiL7ZT1H-PV1s4cODk8ei9p5lvquo1ow2jTLzbN8YsueGUdQ0VTWk9qc5Zz9ta9K14Wmoq21oOip1VL1LaU0qHTqrn1RnvlKCCy_Pqfgc2h5jIZprQZudvSb5Dcr1mGxYkYSJfcYaMI9nMc7hFj86SS1wgh0NwmMtvi_NMbiL4dJjBZ8gueOI8-VIq9DmRXy7fkR14G7wjG4-Lg5fVswnmhK8e34vq--7jzfayvrr-9Hm7uaptJ2Wuu5YbBlaZjqOSoHq0fOQ9R9NJDkZOrBdoBrC0VROFsh9Ap6AfhlYZM9r2onp7yj3E8HPFlPXiki0Dg8ewJl38TA2Mclmk_CS1MaQUcdKH6BaID5pRfeSt9_rIWx95ayp0aRXTm8f81Sw4_rX8AVwE708CLFveO4w62ULF4uhi4a3H4P6f_-Efu52ddxbmH_iAaR_W6As_zXTimupvx4sfD846SlshZPsb4-Cnyw</recordid><startdate>20141001</startdate><enddate>20141001</enddate><creator>Ayas, Mouhab</creator><creator>Siddiqui, Khawar</creator><creator>Al-Jefri, Abdullah</creator><creator>El-Solh, Hassan</creator><creator>Al-Ahmari, Ali</creator><creator>Khairy, Ashraf</creator><creator>Markiz, Samer</creator><creator>Shahin, Hasan</creator><creator>Al-Musa, Abdulrahman</creator><creator>Al-Seraihy, Amal</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8732-5611</orcidid></search><sort><creationdate>20141001</creationdate><title>Factors Affecting the Outcome of Related Allogeneic Hematopoietic Cell Transplantation in Patients with Fanconi Anemia</title><author>Ayas, Mouhab ; Siddiqui, Khawar ; Al-Jefri, Abdullah ; El-Solh, Hassan ; Al-Ahmari, Ali ; Khairy, Ashraf ; Markiz, Samer ; Shahin, Hasan ; Al-Musa, Abdulrahman ; Al-Seraihy, Amal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c488t-432b1ac9b42e98a95ec2d252eb482ab8f156eb7ac039f0a007aa49a57739bbdc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Carcinoma, Squamous Cell - chemically induced</topic><topic>Carcinoma, Squamous Cell - immunology</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cyclophosphamide</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Cystitis - chemically induced</topic><topic>Cystitis - immunology</topic><topic>Cystitis - mortality</topic><topic>Cystitis - pathology</topic><topic>Fanconi anemia</topic><topic>Fanconi Anemia - immunology</topic><topic>Fanconi Anemia - mortality</topic><topic>Fanconi Anemia - pathology</topic><topic>Fanconi Anemia - therapy</topic><topic>Female</topic><topic>Gamma Rays - adverse effects</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hemorrhage - chemically induced</topic><topic>Hemorrhage - immunology</topic><topic>Hemorrhage - mortality</topic><topic>Hemorrhage - pathology</topic><topic>Histocompatibility Testing</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>Myeloablative Agonists - adverse effects</topic><topic>Oropharyngeal Neoplasms - chemically induced</topic><topic>Oropharyngeal Neoplasms - immunology</topic><topic>Oropharyngeal Neoplasms - mortality</topic><topic>Oropharyngeal Neoplasms - pathology</topic><topic>Radiation</topic><topic>Retrospective Studies</topic><topic>Siblings</topic><topic>Stem cell transplantation</topic><topic>Survival Analysis</topic><topic>Transplantation Conditioning - methods</topic><topic>Transplantation, Homologous</topic><topic>Unrelated Donors</topic><topic>Vidarabine - adverse effects</topic><topic>Vidarabine - analogs & derivatives</topic><toplevel>online_resources</toplevel><creatorcontrib>Ayas, Mouhab</creatorcontrib><creatorcontrib>Siddiqui, Khawar</creatorcontrib><creatorcontrib>Al-Jefri, Abdullah</creatorcontrib><creatorcontrib>El-Solh, Hassan</creatorcontrib><creatorcontrib>Al-Ahmari, Ali</creatorcontrib><creatorcontrib>Khairy, Ashraf</creatorcontrib><creatorcontrib>Markiz, Samer</creatorcontrib><creatorcontrib>Shahin, Hasan</creatorcontrib><creatorcontrib>Al-Musa, Abdulrahman</creatorcontrib><creatorcontrib>Al-Seraihy, Amal</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biology of blood and marrow transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ayas, Mouhab</au><au>Siddiqui, Khawar</au><au>Al-Jefri, Abdullah</au><au>El-Solh, Hassan</au><au>Al-Ahmari, Ali</au><au>Khairy, Ashraf</au><au>Markiz, Samer</au><au>Shahin, Hasan</au><au>Al-Musa, Abdulrahman</au><au>Al-Seraihy, Amal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Factors Affecting the Outcome of Related Allogeneic Hematopoietic Cell Transplantation in Patients with Fanconi Anemia</atitle><jtitle>Biology of blood and marrow transplantation</jtitle><addtitle>Biol Blood Marrow Transplant</addtitle><date>2014-10-01</date><risdate>2014</risdate><volume>20</volume><issue>10</issue><spage>1599</spage><epage>1603</epage><pages>1599-1603</pages><issn>1083-8791</issn><eissn>1523-6536</eissn><abstract>Abstract Hematopoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi Anemia (FA), and it is generally accepted that these patients should receive low-intensity conditioning because of the underlying DNA repair defect in their cells. Outcomes for recipients of matched related HCT have generally been favorable, but only a few studies have scrutinized the factors that may affect the eventual outcome of these patients. This retrospective analysis of 94 pediatric patients with FA who underwent related HCT at King Faisal Specialist Hospital & Research Center was carried out to attempt to identify factors that may affect outcome. Results showed overall survival (OS) probabilities of 92.5%, 89%, and 86% at 1, 5, and 10 years, respectively. In univariate analysis, use of higher dose cyclophosphamide (CY) (60 mg/kg) conditioning was associated with a better 10-year OS than lower dose CY (20 mg/kg) conditioning (91% versus 82%, respectively; P = .035), and use of radiation-containing regimens was associated with a significantly lower 10-year OS than nonradiation regimens (76% versus 91%, respectively; P = .005). Of the 4 regimens used in this study, the fludarabine-based regimen was associated with the highest survival (95.2%; P = .034). The use of the higher dose CY (60 mg/kg) was associated with a significantly increased incidence of hemorrhagic cystitis (HC) (20% versus 5.6% respectively; P = .049). Three patients (3%) developed squamous cell carcinoma (2 oropharyngeal and 1 genitourinary), at 9.4, 5.4, and 13.3 years after HCT; 2 of them had radiation-containing conditioning. In conclusion, our data suggest that although using a higher dose CY (60 mg/kg) conditioning regimen may be associated with better survival, it is also associated with a significantly increased risk of HC. The addition of fludarabine to the low-dose CY (20 mg/kg) is associated with the best survival. On the other hand, radiation-containing regimens are associated with significantly lower survival.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24960628</pmid><doi>10.1016/j.bbmt.2014.06.016</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-8732-5611</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1083-8791 |
ispartof | Biology of blood and marrow transplantation, 2014-10, Vol.20 (10), p.1599-1603 |
issn | 1083-8791 1523-6536 |
language | eng |
recordid | cdi_proquest_miscellaneous_1561971028 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Adolescent Carcinoma, Squamous Cell - chemically induced Carcinoma, Squamous Cell - immunology Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - pathology Child Child, Preschool Cyclophosphamide Cyclophosphamide - adverse effects Cystitis - chemically induced Cystitis - immunology Cystitis - mortality Cystitis - pathology Fanconi anemia Fanconi Anemia - immunology Fanconi Anemia - mortality Fanconi Anemia - pathology Fanconi Anemia - therapy Female Gamma Rays - adverse effects Hematology, Oncology and Palliative Medicine Hematopoietic Stem Cell Transplantation Hemorrhage - chemically induced Hemorrhage - immunology Hemorrhage - mortality Hemorrhage - pathology Histocompatibility Testing Humans Infant Male Myeloablative Agonists - adverse effects Oropharyngeal Neoplasms - chemically induced Oropharyngeal Neoplasms - immunology Oropharyngeal Neoplasms - mortality Oropharyngeal Neoplasms - pathology Radiation Retrospective Studies Siblings Stem cell transplantation Survival Analysis Transplantation Conditioning - methods Transplantation, Homologous Unrelated Donors Vidarabine - adverse effects Vidarabine - analogs & derivatives |
title | Factors Affecting the Outcome of Related Allogeneic Hematopoietic Cell Transplantation in Patients with Fanconi Anemia |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T19%3A43%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Factors%20Affecting%20the%20Outcome%20of%20Related%20Allogeneic%20Hematopoietic%20Cell%20Transplantation%20in%20Patients%20with%20Fanconi%20Anemia&rft.jtitle=Biology%20of%20blood%20and%20marrow%20transplantation&rft.au=Ayas,%20Mouhab&rft.date=2014-10-01&rft.volume=20&rft.issue=10&rft.spage=1599&rft.epage=1603&rft.pages=1599-1603&rft.issn=1083-8791&rft.eissn=1523-6536&rft_id=info:doi/10.1016/j.bbmt.2014.06.016&rft_dat=%3Cproquest_cross%3E1561971028%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1561971028&rft_id=info:pmid/24960628&rft_els_id=S1083879114003668&rfr_iscdi=true |